Topotecan as a second-line therapy in patients with ovarian and primary peritoneal cancer: initial response and long-term follow-up

The purpose of this study was to evaluate the role of topotecan at a dose of 5-day standard 1.5 mg/m2/day in patients with relapsed ovarian cancer. Two different groups of patients were included. In group 1, 23 patients who had bidemensionally measurable disease were examined, and in group 2, 11 patients were given topotecan after positive second-look laparotomy (SLL) were analyzed. Total number of cycles was 190 with a median value of six cycles. In group 1, three (13%) patients had complete response (CR) and seven (30%) had partial response (PR) with a total response rate of 43%. Six patients (27%) had stable disease (SD), and seven (30%) had progressive disease (PD). Median survival durations for patients with CR, PR, SD, and PD were 35, 14, 15, and two months, respectively. In group 2, two patients had PD during treatment. The remaining nine patients had no measurable disase or marker relapse at the end of treatment period. Median survival duration was 27 months. In conclusion, topotecan had significant antitumor activity as a second-line therapy in relapsed ovarian cancer patients with measurable disease. In a subgroup of patients with positive second-look laparotomy topotecan was also associated with long median survival duration.

Ovarian cancer; Recurrence; Topotecan; Second-line; Toxicity

[1] DiSaia P.J., Creasman W.T.: "Epithelial ovarian cancer". In: DiSaia P.J., Creasman W.T. (eds.). Clinical Gynecologic Oncology, Sixth Edition. Mosby Inc., 289.

[2] Hsiang Y.H., Liu L.F.: "Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin". Cancer Res., 1988, 48, 1722.

[3] Creemers G.J., Lund B., Verweij J.: "Topoisomerase I inhibitors: topotecan and irenotecan". Cancer Treat. Rev., 1994, 20, 73.

[4] Creerners G.J., Bolis G., Gore M. et al.: "Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study". J. Clin. Oncol., 1996, 14, 3056.

[5] Bookman M.A., Malmstrom H., Bolis G., Gordon A., Lissoni A., Krebs J.B., Fields S.Z.: "Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel". J. Clin. Oneal., 1998, 16, 3345.

[6] McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., Dunton C.J.: "Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma· A Gynecologic Oncology Group Study". J. Clin. Oncol., 2000, 18, 1062.

[7] Swisher E.M., Mutch D.G., Rader J.S., Elbendary A., Herzog T.J "Topotecan in platinum- and paclitaxel-resistant ovarian cancer". Gynecol. Oneal., 1997, 66, 480.

[8] Kudelka A.P., Tresukosol D., Edwards C.L. et al.: "Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma". J. Clin. Oncol., 1996, 14, 1552.

[9] Rodriguez M.. Rose P.G.: "Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer". Gynecol. Oneal., 2001, 83, 257.

[10] Hoskins P., Eisenhauer E., Beare S. et al.: "Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study". J. Clin. Oncol., 1998, 16, 2233.

[11] Gynecologic Oncology Group Common Toxicity Criteria. In DiSaia P.J., Creasman W.T. (eds.). Clinical Gynecologic Oncology, 6" edition, St. Louis, Mosby Inc., 621.

[12] Ozals R.F., Schwartz P.E., Eifel P.J.: "Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma". In: DeVita Jr. V.T., Hellman S., Rosenberg S.A. (eds.). Cancer: Principles and Practice of Oncology, 6"', edition. Philadelphia: Lippincott Willams & Wilkins, 2001, 2, 1597.

[13] Ozols R.F.: "Update of the NCCN ovarian cancer practice guidelines". Oncology (Huntingt), 1997, 11, 95.

[14] Malik I.A.: "An open label evaluation of topotecan in patients with relapsed or refractory epithelial ovarian cancer - single institution experience in a developing country". Int. J. Gynecol. Cancer, 2000,10, 443.

[5] ten Bokkel Huinink W., Gore M., Carmichael J. et al.:'Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer". J. Clin. Oneal., 1997, 15, 2183.

[16] Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J.: "Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan". J. Clin. Oncol., 2001, 19, 3312.

[17] Cesano A., Lane S.R., Poulin R., Ross G.，Fields S.Z.: "Stabihzation of disease as a useful predictor of survival following secondline chemotherapy in small cell lung cancer and ovarian cancer patients". Int. J. Oneal., 1999, 15, 1233.

[18] Armstrong D., O'Reilly S.: "Clinical Guidelines for Managmg Topotecan-Related Hematologic Toxicity". Oncologist, 1998, 3, 4.

[19] Morris R., Munkarah A.: "Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer". Oncologist, 2002, 7 (suppl. 5), 29.

[20] Morris R.T.: "Weekly topotecan in the management of ovanan cancer". Gynecol. Oneal., 2003, 90 (3 Pt 2), S34.